• Teva director Roberto Mignone disclosed the sale of 367,600 ordinary shares on Sept. 18, 2026.
• Average sale price USD 39.06 per share.
• Transaction left zero shares held indirectly through Swiftcurrent Master Fund Ltd.
• Mignone reported 119,807 ordinary shares held directly following the sale.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Teva Pharmaceutical Industries Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-397959), on September 22, 2026, and is solely responsible for the information contained therein.